Ariceum Therapeutics (Ariceum) is a private biotech company developing a novel, first in class radiopharmaceutical product for the diagnosis and targeted radiotherapy of certain hard-to-treat cancers.
Ariceum Therapeutics has raised €25M across 1 funding round from 3 investors, most recently a Series A round in Jun 2022. Based in Berlin, Germany; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-06-10 | Series A | €25M |
| EQT Life Sciences,HealthCap,Ipsen Pharma |
| View deal → |
